The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider, and the trend lines are moving in opposite directions. Orange Book patent challenges have fallen off a cliff — down over 86% from peak — while biologic patent filings at the PTAB have climbed back above the Orange Book count every year since FY2021. For IP teams, portfolio managers, and R&D leads trying to allocate litigation budget and position for the next loss-of-exclusivity wave, this divergence is the most consequential data set in pharma patent strategy right now.
This guide drills into the USPTO’s cumulative study data (updated through July 2025), the structural mechanics behind each patent framework, real-world IP valuation breakdowns, and what the numbers mean for your next board presentation, litigation calendar, or acquisition thesis.
The Two Frameworks: Orange Book, Purple Book, and Why the Difference Matters
Orange Book Patent Linkage and the Hatch-Waxman Architecture
The Orange Book — formally the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations — has governed small-molecule generic entry since the Drug Price Competition and Patent Term Restoration Act of 1984. Every NDA approved under section 505(b) carries an Orange Book entry that must list patents claiming the active ingredient, approved formulations, and approved methods of use. That list is not optional, and it is not advisory. It triggers automatic 30-month stays when a generic applicant files a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed by the generic product.
The commercial logic is tight. The first generic applicant to file a Paragraph IV certification earns 180-day market exclusivity from the date of commercial launch, provided no court finds the patent invalid or not infringed. That 180-day window is worth hundreds of millions of dollars for high-revenue branded drugs, which is why generic companies devote substantial legal resources to identifying challengeable Orange Book patents before filing their ANDAs.
What the Orange Book does not permit matters equally. Under 21 C.F.R. § 314.53(b), process patents, packaging patents, metabolite patents, and intermediate patents cannot be listed. The listing is limited to active ingredient claims, formulation claims, and method-of-use claims tied to an approved indication. This narrowing shapes the entire strategic terrain: brands cannot simply list every patent they hold, and generics know precisely which patents they must certify around or challenge.
The 2020 Orange Book Transparency Act, now fully implemented, added further teeth. It clarified that improper Orange Book listings constitute patent misuse and gave the FTC explicit authority to challenge listings it views as anticompetitive. In 2023, the FTC sent warning letters to brand companies regarding device patents listed for drug-device combination products, signaling active enforcement intent rather than passive monitoring. The net effect is a smaller, higher-quality Orange Book — which has downstream consequences for PTAB petition volumes, as discussed below.
IP Valuation of Orange Book Portfolios
For analysts modeling brand revenue durability, the Orange Book patent portfolio is a primary input. The key metrics are the number of listed patents per product, the legal strength of the longest-dated Orange Book claim, and whether any patents carry Patent Term Extensions (PTEs) granted under 35 U.S.C. § 156.
A PTE can extend a single patent by up to five years to compensate for FDA review time, with a ceiling of 14 years of effective patent life post-approval. Only one PTE can be granted per product, and it attaches to the patent most directly covering the approved active ingredient, not to formulation or method-of-use patents. For valuation purposes, this creates a two-tier structure: the PTE-bearing compound patent is the primary moat, and formulation or method patents are secondary positions that may or may not survive a Paragraph IV challenge. Portfolio managers should model the LOE date off the PTE patent first, then run scenario analysis on the secondary patents’ survival probability.
NCE (New Chemical Entity) exclusivity adds another layer. FDA grants five years of data exclusivity for drugs containing a previously unapproved chemical entity, during which generics cannot even file an ANDA with a Paragraph IV certification (they can file after four years if challenging patents). This exclusivity is separate from patent protection and is not listed in the Orange Book — it is enforced administratively. The interaction between NCE exclusivity, the PTE, and Orange Book listings defines the realistic commercial runway for any branded small-molecule product.
The Purple Book and BPCIA Patent Dance
Biologics live in a different regulatory universe. Under the Biologics Price Competition and Innovation Act of 2009 (BPCIA), reference biologic products receive 12 years of data exclusivity from their date of licensure, far exceeding the five-year NCE exclusivity available to small molecules. The first four years of that 12-year period are an absolute bar on biosimilar ANDA filings. The remaining eight years run in parallel with patent protection, creating overlapping and sometimes redundant exclusivity periods.
The BPCIA’s patent disclosure mechanism — known colloquially as the ‘patent dance’ — requires a biosimilar applicant to share its aBLA with the reference product sponsor within 20 days of FDA filing acceptance. The sponsor then has 60 days to identify patents it believes would be infringed. The parties negotiate a list of patents to be litigated immediately in a ‘first wave,’ and any remaining patents can be asserted in a ‘second wave’ triggered when the biosimilar applicant gives 180 days’ notice of commercial marketing. Participation in the dance is technically optional for the applicant, but skipping it removes the 180-day notice protection and invites preliminary injunction risk.
The Purple Book, maintained by FDA’s Center for Drug Evaluation and Research (CDER), currently lists product licensure information and biosimilar interchangeability designations. The Biological Product Patent Transparency provision enacted in December 2022 added a new disclosure layer: reference product sponsors must now publish, within 30 days of receiving notice of a biosimilar application, a list of patents they believe cover their product. FDA maintains that list and is working toward full integration with Purple Book infrastructure. This is a material change — it mirrors the Orange Book’s patent-linkage architecture and will give biosimilar developers a roadmap to challenging portfolios that previously required the patent dance to uncover.
IP Valuation of Biologic Patent Portfolios
Biologic patent portfolios are valued differently from Orange Book portfolios because the underlying claims are more complex and more numerous. A typical blockbuster biologic will carry patents in at least five distinct technical categories: sequence and structural claims covering the molecular entity itself, formulation patents covering excipients and concentration, manufacturing process patents covering cell lines and purification methods, device patents covering prefilled syringes or autoinjectors, and method-of-treatment patents covering approved indications.
Each layer adds independently defensible time. Sequence patents typically expire within 20 years of filing but can carry PTEs. Formulation patents, filed later, may expire five to eight years after the sequence patent. Device patents, filed last, often extend protection another two to five years. The cumulative effect is what practitioners call a ‘patent thicket’: no single patent is the moat, the thicket itself is.
For institutional investors, this layered structure means that a biologic’s true LOE date is not the sequence patent expiry but rather the date by which a biosimilar can enter the market commercially without facing patent-infringement liability on any one of those layers — or negotiate a settlement that grants a license. Modelers should run separate survival probability curves for each patent layer, discount the thicket premium by the probability of successful PTAB challenge (roughly 39% institution denial for biologics, per current USPTO data), and adjust for political risk around patent cap legislation like S.150 or the Affordable Prescriptions for Patients Act.
Key Takeaways: Framework and Valuation
Orange Book listings are statutorily limited to compound, formulation, and method-of-use claims, which creates a clearly defined and judicially testable patent perimeter.
Purple Book patent disclosure is evolving. The 2022 BPPT provision will eventually replicate Orange Book-style patent linkage for biologics, materially changing how biosimilar developers plan Paragraph IV-equivalent challenges.
PTE analysis is the anchor for small-molecule IP valuation. One patent, one extension, up to five years, capped at 14 years of post-approval life.
Biologic portfolio valuation requires separate survival probability modeling across five patent layers. The realistic LOE date for any blockbuster biologic is a probability-weighted range, not a single date.
FTC enforcement against improper Orange Book listings is active. Any listed patent facing FTC scrutiny carries elevated litigation risk and may be delisted administratively, collapsing a 30-month stay.
The PTAB Data: What the Numbers Actually Show
Orange Book Petition Volume Has Collapsed
The USPTO’s updated study, which covers AIA petition data from FY2013 through July 2025, documents a dramatic and sustained decline in PTAB challenges to Orange Book patents. In FY2015 and FY2016, Orange Book patents drew more than 100 PTAB petitions per year and accounted for 7.5% of all AIA petitions. By FY2020, petition volume had fallen into the range of 6 to 20 per year. By FY2023 and FY2024, Orange Book patents had dropped to approximately 1% of all AIA petitions — a proportional decline of roughly 86% from the 2016 peak.
Cumulatively, Orange Book patents account for only 3% of all AIA petitions since FY2013. The petition type breakdown is lopsided: 96% of Orange Book proceedings are IPRs. Between FY2022 and FY2024, only zero to two PGR petitions per year targeted Orange Book patents. The near-total absence of PGRs reflects the patent age profile of the Orange Book: PGR petitions must be filed within nine months of patent grant, which means they are available only against recently issued patents, and the Orange Book’s most commercially important patents are generally not newly granted.
The institution rate for Orange Book patents sits at 62% cumulatively. That is slightly above the 59% cumulative rate for biologics and slightly below the 64% rate for all patents combined. The difference between Orange Book and all-patent institution rates is unlikely to be statistically significant given the sample size (478 Orange Book petitions versus over 12,500 total petitions). What is statistically meaningful is the post-institution outcome.
Orange Book Patents Win at the PTAB More Often Than Biologic Patents
Once a PTAB proceeding on an Orange Book patent is instituted, the patent owner fares better than in any other pharma category. Approximately 21% of all Orange Book patent petitions result in a final written decision (FWD) finding all challenged claims patentable — meaning the patent survives intact. By contrast, only 6% of biologic patent petitions result in an all-claims-patentable FWD.
Stated from the challenger’s perspective: when an Orange Book IPR reaches an FWD, the patent is invalidated (all claims unpatentable) roughly 25% of the time. When a biologic IPR or PGR reaches an FWD, the patent is invalidated roughly 22% of the time on a petition-level basis. That number is higher when expressed as a fraction of instituted proceedings: among instituted biologic proceedings, all claims unpatentable is the most common outcome at 38%, compared to a mixed outcome where some claims survive.
Settlement rates offer another lens. Both Orange Book and biologic proceedings settle at lower rates than the overall PTAB average. This is structurally predictable. Brand companies in pharma have more to lose from precedential invalidity findings than the typical patent holder in industrial technology, so they fight rather than settle. Generic and biosim challengers, knowing this, press harder precisely because the brand is unlikely to offer favorable settlement terms early.
Biologic Petition Volume Is Rising and Has Outpaced Orange Book Since FY2021
In FY2017, biologic patent petitions hit 75, representing 3.9% of all AIA petitions — the highest point for biologics. After a dip, the number of biologic petitions rose from 8 in FY2020 to 38 in FY2023, and biologic petitions have exceeded Orange Book petitions every year since FY2021. Cumulatively, biologics account for 2% of all AIA petitions.
The petition type split for biologics is almost the mirror image of Orange Book: biologic patents account for approximately 90% of all PGR petitions ever filed at the PTAB. This is not coincidental. PGR allows challenges on any ground of invalidity, including Section 112 written-description and enablement challenges. Biologic patents — covering engineered protein sequences, complex manufacturing processes, and multi-component formulations — are especially vulnerable to written-description challenges because the claimed scope of a biologic patent often reaches beyond what the specification demonstrates experimentally. No such vulnerability exists for most small-molecule Orange Book patents, where the chemistry is well-characterized and fully enabled.
The timing of PGR availability is also strategically critical. PGR is available only within nine months of patent grant. For biosimilar developers, this creates a ‘use it or lose it’ window: miss the deadline on a newly issued biologic manufacturing patent and the only remaining PTAB option is IPR, which limits challenges to prior art grounds. Developers tracking biologic patent issuance and filing PGRs within that nine-month window have a significantly stronger invalidity argument than those who wait.
2025 and Beyond: PTAB Director Squires and the Shifting Landscape
A structural shift that any current analysis must address is the reform program implemented by USPTO Director John Squires, effective October 2025. Director Squires centralized institution decisions under direct director oversight, proposed new rules on serial petitions, and tightened real-party-in-interest disclosure requirements. These changes have materially reduced IPR institution rates across all technology categories in the short term.
For the pharma sector specifically, medical and pharmaceutical petitions remained relatively steady at 12.7% of PTAB activity through 2025, even as overall institution rates declined. The practical consequence is that challengers are migrating toward ex parte reexaminations as an alternative pathway. Ex parte reexam request grants run at roughly 95% (versus 63% institution for IPRs), but claim cancellation rates are lower — approximately 14% direct cancellation, though about 62% of patents undergoing reexamination end up with modified or cancelled claims. Ex parte reexam filings surged 66.1% to 726 in calendar year 2025, directly tracking the IPR institution decline.
For biosimilar developers, this environment reinforces the strategic priority of PGR over IPR. PGR is available only in the nine-month post-grant window, which is shorter than the IPR window, but the Director’s reforms have been less disruptive to PGR practice than to IPR practice. Teams that monitor biologic patent issuance dates and have PGR petitions ready to file within the window are better positioned than those dependent on post-nine-month IPR filings.
Investment Strategy: Reading the PTAB Data for Portfolio Positioning
For institutional investors, the PTAB data translate into specific portfolio signals.
On the originator brand side, a brand biologic with a recently issued manufacturing process patent faces material PGR risk in the nine months after grant. IP teams at originator companies that are asleep to this window are creating balance sheet exposure that does not appear in most analyst models. The proper valuation treatment is to apply a PGR risk haircut — conservatively, a 20 to 30% probability of significant claim modification — to the LOE-extending value of any biologic patent issued within the past nine months. If that patent is the only defense against a high-priority biosimilar, the LOE date should be range-modeled, not point-estimated.
For generics, the Orange Book data send a clear message. The 21% all-claims-patentable outcome rate means that roughly one in five Orange Book PTAB campaigns ends with the challenger paying litigation costs and getting nothing. The expected value of an Orange Book IPR is lower than it was in 2015. Teams should model the relative return of PTAB petition versus Paragraph IV district court litigation (with the 180-day exclusivity carrot) versus skinny-label launch. In many cases, the 180-day exclusivity is more valuable than any PTAB outcome. The economics of a solo Paragraph IV filer who secures 180-day exclusivity and wins district court litigation dwarf the economics of a PTAB winner with no exclusivity.
For biosimilar developers, the asymmetry runs the other way. Only 6% of biologic patent petitions end with all challenged claims surviving. The expected value of a well-constructed biologic PTAB petition is materially higher than for Orange Book. Biosimilar investment cases should model PTAB success as a probability-weighted acceleration of LOE dates, and that probability should reflect the 94% rate at which biologic patents do not walk away from PTAB with all claims intact.
Key Takeaways: PTAB Statistics
Orange Book PTAB petitions have fallen from 7.5% of all AIA filings in FY2016 to approximately 1% in FY2024, a volume collapse driven by patent exhaustion, Hatch-Waxman economics, and improved Orange Book listing quality.
Biologic petitions have outpaced Orange Book petitions every year since FY2021 and now represent approximately 2% of cumulative AIA filings with a rising annual trajectory.
Orange Book patents survive PTAB at a higher rate: 21% all-claims-patentable versus 6% for biologics in final written decisions.
Biologics dominate the PGR docket, accounting for approximately 90% of all PGR petitions ever filed. This reflects Section 112 written-description vulnerability specific to complex molecular claims.
Director Squires’ 2025 PTAB reforms have reduced IPR institution rates and driven a 66% surge in ex parte reexamination filings. Biosimilar teams must prioritize PGR filings within the nine-month post-grant window.
Settlement rates at PTAB are lower for both Orange Book and biologic cases than for overall patent proceedings, reflecting the high strategic stakes for brand companies.
AbbVie’s Humira: The Definitive IP Valuation Case Study
How the Thicket Was Built
Humira (adalimumab) launched in 2002 following Abbott Laboratories’ 2000 acquisition of Knoll Pharmaceuticals from BASF, which carried the D2E7 antibody program. The originating compound patents — which AbbVie did not invent — expired in 2016. What AbbVie built after acquisition is the textbook definition of secondary patenting as a commercial strategy.
AbbVie filed approximately 311 patent applications on Humira in the United States. Of those, 132 were granted, creating a patent portfolio that extends paper coverage through 2034. Critically, 90% of those filings came after Humira received FDA approval in 2002, and nearly half were filed in 2014 or later — timed specifically to coincide with the expiration of the originating compound patent and the anticipated biosimilar wave. The strategy was explicit: construct a secondary patent portfolio dense enough that no biosimilar applicant could confidently certify non-infringement on every claim.
Humira generated over $16 billion in U.S. domestic sales in 2020 alone and nearly $20 billion globally. Its U.S. list price increased by approximately 470% over its commercial life, reaching roughly $7,000 per month’s supply. AbbVie raised that price multiple times in the years leading up to biosimilar entry, capturing price-versus-volume trade-off models that assumed slow biosimilar penetration.
The Patent Dance and Settlement Economics
Beginning in 2015, biosimilar applicants began filing aBLAs for adalimumab biosimilars, triggering the BPCIA patent dance. AbbVie identified over 60 patents it intended to assert against individual biosimilar challengers — a volume that made district court litigation economically devastating for any single challenger.
The result was predictable. Every biosimilar applicant ultimately settled with AbbVie rather than litigating through the full portfolio. Settlement terms followed a consistent structure: licenses to launch in the European market in October 2018, with commitment to delay U.S. market entry until January 2023, plus royalty payments to AbbVie on U.S. biosimilar sales after launch. AbbVie received royalties from its own competition. The five-year delay between European biosimilar entry (2018) and U.S. biosimilar entry (2023) is estimated to have cost the American healthcare system between $14.4 billion and $19 billion in foregone savings.
One challenger, Alvotech, elected not to settle immediately and filed suit alleging that AbbVie had patented inventions it did not actually use in manufacturing Humira and had sought multiple patents on the same inventions across different patent families to create confusion. Those allegations were never fully adjudicated — Alvotech ultimately settled — but they document in court filings the mechanics of an aggressive secondary patent strategy.
When biosimilars finally entered the U.S. market in 2023, Humira’s effective price decreased by approximately 38%. The formulation most commonly prescribed — the high-concentration, citrate-free version AbbVie launched commercially in 2018 — did not face a biosimilar competitor until 2024, when interchangeable biosimilar designations became available for those formulations.
Legislative and Antitrust Fallout
The Humira saga directly shaped the legislative environment for biologic patents. The Affordable Prescriptions for Patients Act (S.150) proposes capping the number of patents a biologic manufacturer can assert against any single biosimilar applicant. The BPCIA currently imposes no such limit, which is the statutory gap AbbVie exploited. S.150 would close that gap by limiting patent assertions to a defined number per product and per proceeding.
Class action antitrust plaintiffs alleged that AbbVie monopolized the U.S. market by creating and asserting a patent thicket of invalid and unenforceable patents and by engaging in market allocation through the Europe/U.S. settlement structure. The Northern District of Illinois dismissed those claims at the motion-to-dismiss stage, finding that AbbVie’s patent thicket strategy was immunized by the Noerr-Pennington doctrine — which protects the right to petition government (including courts) — and that the existence of even one valid and infringed patent would have precluded biosimilar entry regardless of the broader portfolio. The antitrust door on patent thicket claims remains legally unsettled after that ruling.
For Merck’s Keytruda (pembrolizumab), the pharmaceutical industry is watching closely. Merck has secured 129 patents on Keytruda, including claims on excipient concentrations and sterile packaging. Keytruda’s primary composition-of-matter patents expire in the early 2030s. If Merck deploys the Humira playbook, biosimilar entry could be delayed into the late 2030s. Given that Keytruda generated approximately $25 billion in global revenue in 2024, the commercial stakes exceed even Humira.
IP Valuation Takeaway for Humira and Its Successors
Analysts who modeled AbbVie’s Humira LOE based on the 2016 primary patent expiry were wrong by seven years. The correct valuation framework was: primary patent expiry date plus probability-weighted survival duration of the thicket. For Humira, the thicket survived intact through settlement. Extrapolating to future blockbuster biologics, the relevant IP valuation inputs are the number of secondary patents filed post-approval, the proportion of those patents in manufacturing-process categories (which the BPCIA can assert without limitation), and the financial capacity of the originator to sustain multi-front litigation against each biosimilar applicant simultaneously.
Key Takeaways: Humira and the Patent Thicket Model
AbbVie filed 311 Humira patent applications, 90% of them post-approval. The portfolio held up not because every patent was valid, but because the litigation cost of challenging all of them simultaneously exceeded any single biosimilar applicant’s risk tolerance.
The BPCIA’s absence of an assertion cap is the structural gap that makes the Humira playbook repeatable. S.150, if enacted, changes the calculus materially for every blockbuster biologic with a large secondary patent portfolio.
Settlement economics — royalties paid to AbbVie on competitors’ sales — mean that originator companies can monetize their thicket even after competitive entry. Analysts should model post-LOE royalty streams when evaluating companies with this structure.
The five-year Europe-to-U.S. launch delay cost the U.S. system an estimated $14.4 to $19 billion. Payers and PBMs are incorporating this data into formulary strategy for the next biologic LOE wave.
Keytruda is the next system-scale test of the patent thicket model. Monitor Merck’s secondary patent filing rate and category mix closely.
Comparing the Two Patent Strategies: A Technical Framework
Claim Scope and Listing Eligibility
Orange Book patent coverage is narrow by design. The CFR restricts listings to compound claims (the drug substance), formulation claims (an approved dosage form), and method-of-use claims for an approved indication. Every claim in a listed Orange Book patent has been, at least nominally, reviewed by FDA for listing eligibility. This restriction creates a defined target set for generic challengers and a defined scope for Paragraph IV certifications.
Biologic patent coverage is broad by practice. The BPCIA does not replicate the Orange Book’s listing restrictions. A reference product sponsor can assert in the patent dance any patent it believes would be infringed, which includes manufacturing process patents, cell-line patents, device patents, and method-of-treatment patents for non-approved indications. The strategic asymmetry is significant: generic companies face a known, bounded Orange Book patent list; biosimilar companies face an open-ended patent assertion threat that was historically undisclosed until the patent dance began.
The 2022 BPPT provision is changing this. Reference product sponsors must now publish their patent list within 30 days of receiving aBLA notice. As FDA builds that disclosure infrastructure into the Purple Book, biosimilar developers will increasingly have the same pre-filing visibility into biologic patent portfolios that generic developers have always had into Orange Book listings.
PTAB Tool Selection: IPR vs. PGR
IPR — Inter Partes Review — is available against any patent more than nine months post-grant. Validity can be challenged only on grounds of prior art under Sections 102 and 103. IPR is the dominant tool for both Orange Book and biologic challenges historically, and it is the almost exclusive tool for Orange Book challenges (96% of Orange Book proceedings are IPRs).
PGR — Post-Grant Review — is available only in the nine months after patent grant. It allows challenges on any ground of invalidity, including Sections 112, 101, and prior art. The broader scope makes PGR particularly powerful against biologic patents, where Section 112 written-description and enablement arguments are often the strongest invalidity grounds. Biologic patents account for approximately 90% of all PGR petitions ever filed at the PTAB.
The practical strategic recommendation for biosimilar teams: monitor biologic patent issuance using real-time USPTO databases, flag every patent in the relevant portfolio with its grant date, and have PGR petition drafts ready to file before the nine-month window closes. A patent that passes the PGR window can only be challenged in IPR, where the invalidity grounds are narrower and the written-description arguments are foreclosed.
Outcome Profiles and What They Imply for Litigation Budgeting
The post-institution outcome data tell a clean story. For Orange Book patents, the patentee wins (all claims survive) roughly 35% of the time in final written decisions, and the petitioner wins (all claims invalidated) roughly 40% of the time, with mixed outcomes making up the remainder. For biologic patents, the patentee wins all-claims-patentable approximately 12% of the time in final written decisions, the petitioner wins all-claims-unpatentable approximately 38% of the time, and the mixed-outcome rate is higher than for Orange Book patents.
For litigation budget modeling: an Orange Book IPR costs roughly $400,000 to $800,000 through final written decision. The expected value of that spend — 40% chance of full win, discounted by 60% institution rate — means the effective win rate on a filed petition is approximately 24%, which must then be compared against the 180-day exclusivity value and the district court alternative. A biologic PGR through final written decision runs $600,000 to $1.2 million given the complexity of claim analysis. The effective win rate — 38% all-claims-unpatentable at FWD, multiplied by 61% institution rate — is approximately 23%, slightly comparable to Orange Book IPR but with broader grounds and higher invalidation rates per instituted proceeding.
The key differentiator is not expected win rate per petition — it is what a win is worth. An Orange Book IPR win triggers an FDA approval pathway and, potentially, 180-day exclusivity. A biologic PGR win removes a blocking patent from a thicket that may contain 60 additional patents. Both outcomes require integration into the broader market entry strategy to assess true expected value.
The Role of Patent Evergreening Roadmaps
Evergreening — the practice of filing secondary patents to extend the effective exclusivity period of a drug beyond the primary patent — operates differently in small-molecule and biologic contexts.
For small molecules, the canonical evergreening tactics include polymorph patents (covering specific crystal forms), enantiomer patents (covering the purified active stereoisomer rather than the racemate), metabolite patents, extended-release formulation patents, and combination patents. None of these can be listed in the Orange Book unless they claim an approved drug product or approved method. A polymorph patent covering a crystal form that does not appear in the approved NDA cannot be listed. The listing restriction limits the evergreening value of many secondary patents for Hatch-Waxman purposes.
For biologics, evergreening tactics are more extensive because the BPCIA imposes no listing restriction equivalent. The common biologic evergreening sequence runs as follows: the originator files a next-generation formulation patent (covering a higher-concentration or modified-excipient version) approximately five to eight years after initial approval, then launches the new formulation commercially and uses formulary contracting and rebate structures to shift patient volume away from the original formulation toward the new one. By the time biosimilars target the original formulation, the market has largely migrated. Biosimilars matching the new formulation face additional development work and the new formulation’s separate patent term. AbbVie’s launch of the citrate-free, high-concentration Humira in 2018 — five years before U.S. biosimilar entry for the original formulation — is the clearest illustration of this tactic.
The biologic evergreening roadmap typically spans three stages. Stage one covers the origination period (years 1 through 8 post-approval): the company files manufacturing-process patents, cell-line patents, and initial formulation patents. Stage two covers the consolidation period (years 8 through 15): the company files device patents (autoinjectors, prefilled syringes), combination patents (biologics paired with companion diagnostics or co-formulated drugs), and method-of-treatment patents for newly approved indications. Stage three covers the defense period (years 15 onward): the company launches reformulated products, pursues interchangeability designation for its own follow-on version to displace biosimilars, and pursues citizen petitions to delay biosimilar approvals on safety grounds. R&D leads at biosimilar companies should map each reference product against this three-stage roadmap to identify where the originator is in the cycle and which patent categories are most likely to require challenge.
Key Takeaways: Technical Strategy Comparison
Orange Book patent challenges are almost exclusively IPRs (96%). Biologic challenges are split between IPR and PGR, with biologics dominating the PGR docket (approximately 90% of all PGRs filed).
PGR is the highest-priority tool for biosimilar developers. The nine-month post-grant window is narrow, the grounds are broader (including Section 112), and the Director Squires reforms have been less disruptive to PGR practice than to IPR practice.
Outcome profiles favor biologic challengers at the post-institution stage: only 12% of biologic patents emerge with all claims intact from a final written decision, compared to 35% for Orange Book patents.
Biologic evergreening follows a three-stage roadmap across the product lifecycle. Biosimilar developers should map each target against this roadmap to identify patent categories ripe for challenge and to predict future formulation switching.
Small-molecule evergreening is constrained by Orange Book listing restrictions. Polymorph, metabolite, and many formulation patents cannot be listed, limiting their Hatch-Waxman value even when the underlying patents are valid.
Global Context: EU, Japan, and the Pre-Approval Challenge Model
The United States is not the only jurisdiction grappling with biologic patent strategy. The European Patent Convention and EU competition law create a markedly different environment, and that environment is now being cited explicitly in U.S. legislative hearings as a model.
In the EU, patent challenges can be filed at the European Patent Office as oppositions within nine months of grant — a timeline and mechanism structurally similar to PTAB PGR. EU competition law, unlike the Noerr-Pennington doctrine in the U.S., does not provide blanket immunity for patent enforcement activities. Originator companies in the EU face genuine antitrust exposure for patent assertion strategies that delay biosimilar entry. The European Commission has issued fines for pay-for-delay settlements and has investigated patent thicket strategies as potential abuses of dominant position.
Biosimilar challengers in Europe routinely file patent oppositions before biosimilar clinical trials are complete, concurrent with development. U.S. law does not currently permit pre-approval patent challenges of equivalent structure — PTAB petitions require a filed petition against a specific issued patent, and IPR/PGR timing constraints apply. The practical consequence is that U.S. biosimilar developers must begin patent challenge planning earlier in development than European counterparts, using PTAB’s IPR and PGR mechanisms as the available substitute for pre-approval opposition.
Japan’s system merits separate note. The Japan Patent Office allows patent invalidation trials (tokkyomukouroukyuu shinshin) at any time after grant, without the IPR’s prior-art-only limitation. Japan’s biologic patent landscape has seen meaningful invalidation activity, and the JPO has been willing to find biologic process patents invalid on enablement grounds. For multinational originator companies, the Japan invalidation track is a secondary front that biosimilar developers can exploit in parallel with PTAB proceedings in the U.S.
The key strategic implication of the global comparison: U.S. biosimilar developers that limit their patent challenge activity to U.S. PTAB proceedings are leaving strategic leverage on the table. Coordinated challenge campaigns — U.S. PTAB PGR, EU EPO opposition, Japan JPO invalidation — on the same patent family create compound pressure on the originator and can surface prior art or claim-scope arguments that strengthen each individual proceeding.
Investment Strategy: Portfolio Positioning for the 2025-2030 LOE Wave
The next five years will see loss-of-exclusivity events for biologics representing an estimated $59 billion in originator revenues — and that number is conservative, based on IQVIA 2023 projections that have since been revised upward. Key products in the LOE pipeline include Stelara (ustekinumab, J&J), Eylea (aflibercept, Regeneron), Dupixent (dupilumab, Sanofi/Regeneron) in the early 2030s, and, most significantly, Keytruda (pembrolizumab, Merck) beginning in the early 2030s.
For investors on the originator side, the PTAB data suggest that biologic patent portfolios will face sustained and increasingly effective challenge from biosimilar developers through PGR and IPR proceedings. The 94% rate at which biologic patents do not survive PTAB with all claims intact is not a future prediction — it is the historical record through mid-2025. Originator companies that have built their LOE forecasts assuming patent thicket durability comparable to AbbVie’s Humira success are likely over-estimating revenue tail durations. The legislative and PTAB environment in 2025 is materially less favorable to patent thicket strategies than it was in 2015.
For investors on the biosimilar side, the PTAB data support a more aggressive investment case for biosimilar programs targeting large-portfolio biologics than the Humira precedent might suggest. The settlement dynamic that defined Humira — where every challenger capitulated rather than litigate — is less likely to repeat for several reasons. First, the biosimilar industry has grown larger and more financially robust. Second, the BPPT provision gives biosimilar developers advance patent visibility they previously lacked. Third, S.150-style legislation, even if not enacted in its current form, signals Congressional willingness to reduce the assertion asymmetry in BPCIA litigation. Fourth, PGR and ex parte reexamination activity on newly issued biologic patents is increasing, driven partly by the Squires-era IPR institution decline.
The strategic positioning for portfolio managers in the 2025-2030 window: overweight biosimilar developers with demonstrated PTAB competency and early-filed PGR portfolios against major reference products; underweight originator franchises whose revenue durability models rest on late-filed secondary biologic patents that have not yet been tested at PTAB; and treat PTAB petition data, available publicly from the USPTO, as a real-time monitoring tool for LOE risk across any biologic investment.
Key Takeaways: Global Context and Investment Positioning
The EU and Japan permit patent challenges earlier in the biosimilar development cycle than the U.S. framework. Coordinated cross-jurisdictional challenge campaigns create compounding pressure on originator patent portfolios.
EU competition law, unlike Noerr-Pennington, provides real antitrust exposure for patent thicket strategies. European biosimilar launch dynamics differ from U.S. dynamics partly for this reason.
The $59 billion biologic LOE wave projected through 2030 by IQVIA creates the largest single opportunity set for biosimilar investment thesis construction in the sector’s history.
Biosimilar developers with active PGR programs against newly issued secondary biologic patents are better positioned than those relying solely on BPCIA dance-based litigation timelines.
The Squires PTAB reforms have increased the strategic premium on PGR (versus IPR) for biologic challengers. Teams should audit their target patent portfolios for newly issued patents within the nine-month PGR window as a first-priority action.
Originator LOE models that assume Humira-style thicket durability are structurally miscalibrated for the current legislative and PTAB environment. Investors should stress-test those models against a 30-50% reduction in thicket durability premium.
How to Use Patent Data Operationally: From Orange Book to PTAB Filing
The gap between patent data availability and operational use in pharma IP teams remains wider than it should be. The following workflow describes how well-resourced teams should be integrating Orange Book, Purple Book, and PTAB data in practice.
For generic developers pursuing ANDA filings, the Orange Book is the starting point but not the endpoint. The Orange Book identifies listed patents, their expiration dates, and patent use codes. Use codes determine which approved indications are covered by a method-of-use patent and therefore which indications require Paragraph IV certification versus which can be carved out in a ‘skinny label’ approach. A generic that launches on a skinny label — omitting the patented indications — avoids infringement of method-of-use patents while still capturing significant market share if the patented indication represents a minority of actual prescriptions.
The PTAB petition record for each Orange Book patent is the next analytical layer. If a patent has survived one or more prior IPR challenges, its claim scope has been narrowed or its validity has been confirmed under the preponderance standard. A patent that survived a prior IPR but had claims amended in the process is both more valid (the surviving claims are battle-tested) and potentially narrower (the amendment may have limited the claims’ scope, opening design-around options). Generic developers should review PTAB prosecution histories on relevant Orange Book patents before deciding whether to pursue Paragraph IV or skinny label.
For biosimilar developers, the analogous workflow starts with the BPPT-published patent list (now available within 30 days of aBLA notice filing) and extends through the biologic patent landscape mapping described above. Each patent should be categorized by type (sequence, formulation, manufacturing, device, method-of-treatment), assigned a priority level based on commercial blocking potential, assessed for PGR eligibility (issued within nine months?), and assigned to an invalidity theory. The invalidity theory should be documented before any PTAB filing decision — PGR filings without a strong Section 112 or prior art theory are unlikely to survive institution under any director’s PTAB regime.
Patent analytics platforms have materially improved the data integration available to teams doing this work. The ability to cross-reference FDA approval databases, USPTO patent records, PTAB proceedings, and ANDA/aBLA filing status in real time changes the speed at which competitive intelligence can be converted into litigation decisions. The teams that have invested in this infrastructure can identify PTAB filing windows, track expiration dates with PTE calculations, and model LOE scenarios in hours rather than weeks.
Final Analysis: Two Markets, One Board, Different Rules
The Orange Book and biologic PTAB trends document a pharma patent landscape that has bifurcated clearly along molecular complexity lines. Small-molecule generic strategy is maturing into a data-driven but relatively stable practice, with PTAB playing a secondary role to Hatch-Waxman district court litigation and 180-day exclusivity. Biologic patent strategy is in active evolution, with PTAB playing a growing and increasingly effective role in clearing patent thickets that were previously assumed to be impassable.
For executives making resource allocation decisions — whether on litigation budget, patent prosecution spend, or BD target prioritization — the data support several clear conclusions. Biologic patent thickets are more vulnerable at PTAB than their volume suggests. The nine-month PGR window on newly issued biologic patents is an underexploited opportunity. The Squires PTAB reforms have changed the IPR landscape but have not reduced the strategic premium on early-filed PGR petitions. And the legislative risk to large secondary biologic patent portfolios is higher in 2025 than it has been at any point since the BPCIA’s enactment in 2009.
The data are public. The USPTO releases updated studies on Orange Book and biologic PTAB proceedings. The question is whether your team is reading those updates, integrating them into your patent valuation models, and acting on them faster than your competitors.
Sources: USPTO PTAB Orange Book/Biologics Study, updated through July 2025 (October 2025); Finnegan, Henderson, Farabow, Garrett & Dunner, ‘Trends in PTAB Trials Involving Drug and Biologic Patents’ (June 2024); Foley & Lardner/JDSupra, ‘Trends in Orange Book and Biologic PTAB Trials’ (August 2023); Mintz, ‘PTAB Statistics Show Interesting Trends for Orange Book and Biologic Patents’ (August 2021); Rothwell Figg Biosimilars Law Bulletin (January 2026); Association for Accessible Medicines, 2023 Generics and Biosimilars Savings Report; SSRN, Knox and Curfman, ‘The Humira Patent Thicket, the Noerr-Pennington Doctrine, and Antitrust’s Patent Problem’ (2022); IQVIA Institute, ‘Global Use of Medicines 2024’; Evernorth Health, ‘How Drugmakers Exploit the Patent System’ (2024).
